Company
Tarsus Pharmaceuticals, Inc.
Headquarters: Irvine, CA, United States
Employees: 20
CEO: Dr. Bobak R. Azamian M.D.
Market Cap
$1.73 Billion
USD as of July 1, 2025
Tarsus Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $233.7 M |
| EBITDA | $-107,750,000 |
| Gross Profit TTM | $161.6 M |
| Profit Margin | -44.91% |
| Operating Margin | -33.55% |
| Quarterly Revenue Growth | 183.70% |
Stocks & Indices
Tarsus Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TARS wb_incandescent